nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—breast cancer	0.714	1	CbGaD
Plerixafor—CXCR4—mammary gland—breast cancer	0.00685	0.141	CbGeAlD
Plerixafor—CXCR4—nipple—breast cancer	0.00567	0.116	CbGeAlD
Plerixafor—CXCR4—embryo—breast cancer	0.00467	0.0961	CbGeAlD
Plerixafor—CXCR4—epithelium—breast cancer	0.00381	0.0784	CbGeAlD
Plerixafor—CXCR4—endometrium—breast cancer	0.00342	0.0703	CbGeAlD
Plerixafor—CXCR4—uterus—breast cancer	0.00315	0.0648	CbGeAlD
Plerixafor—CXCR4—pituitary gland—breast cancer	0.0031	0.0636	CbGeAlD
Plerixafor—CXCR4—adipose tissue—breast cancer	0.00308	0.0634	CbGeAlD
Plerixafor—CXCR4—female reproductive system—breast cancer	0.00283	0.0582	CbGeAlD
Plerixafor—CXCR4—adrenal gland—breast cancer	0.00277	0.0568	CbGeAlD
Plerixafor—CXCR4—bone marrow—breast cancer	0.00268	0.055	CbGeAlD
Plerixafor—CXCR4—female gonad—breast cancer	0.00258	0.053	CbGeAlD
Plerixafor—CXCR4—endocrine gland—breast cancer	0.0024	0.0493	CbGeAlD
Plerixafor—CXCR4—lymph node—breast cancer	0.00166	0.0341	CbGeAlD
Plerixafor—CXCR4—Signaling Pathways—CCL27—breast cancer	9.68e-05	0.000979	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—INHBB—breast cancer	9.68e-05	0.000979	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TLE3—breast cancer	9.68e-05	0.000979	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HEY1—breast cancer	9.58e-05	0.000969	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—EDNRB—breast cancer	9.58e-05	0.000968	CbGpPWpGaD
Plerixafor—CXCR4—Disease—DLL1—breast cancer	9.4e-05	0.00095	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPL23A—breast cancer	9.4e-05	0.00095	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BMPR2—breast cancer	9.23e-05	0.000934	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—DLL4—breast cancer	9.23e-05	0.000934	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HIST1H2BC—breast cancer	9.22e-05	0.000933	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAP2K7—breast cancer	9.22e-05	0.000933	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HIST1H2BK—breast cancer	9.22e-05	0.000933	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL2—breast cancer	9.08e-05	0.000918	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AGTR2—breast cancer	9.08e-05	0.000918	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTHLH—breast cancer	8.98e-05	0.000908	CbGpPWpGaD
Plerixafor—Syncope—Docetaxel—breast cancer	8.91e-05	0.000643	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CDH5—breast cancer	8.85e-05	0.000895	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPS7—breast cancer	8.76e-05	0.000886	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPS8—breast cancer	8.76e-05	0.000886	CbGpPWpGaD
Plerixafor—Loss of consciousness—Docetaxel—breast cancer	8.73e-05	0.00063	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Paclitaxel—breast cancer	8.71e-05	0.000629	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CALCA—breast cancer	8.7e-05	0.00088	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EDNRB—breast cancer	8.7e-05	0.000879	CbGpPWpGaD
Plerixafor—CXCR4—Disease—DKK1—breast cancer	8.69e-05	0.000879	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SFRP2—breast cancer	8.68e-05	0.000878	CbGpPWpGaD
Plerixafor—Malaise—Capecitabine—breast cancer	8.67e-05	0.000626	CcSEcCtD
Plerixafor—Insomnia—Paclitaxel—breast cancer	8.65e-05	0.000624	CcSEcCtD
Plerixafor—Hypersensitivity—Irinotecan—breast cancer	8.64e-05	0.000624	CcSEcCtD
Plerixafor—Hypersensitivity—Mitoxantrone—breast cancer	8.64e-05	0.000624	CcSEcCtD
Plerixafor—Vomiting—Thiotepa—breast cancer	8.63e-05	0.000623	CcSEcCtD
Plerixafor—CXCR4—Disease—ALDOA—breast cancer	8.63e-05	0.000872	CbGpPWpGaD
Plerixafor—Syncope—Capecitabine—breast cancer	8.62e-05	0.000622	CcSEcCtD
Plerixafor—Paraesthesia—Paclitaxel—breast cancer	8.59e-05	0.00062	CcSEcCtD
Plerixafor—Rash—Thiotepa—breast cancer	8.56e-05	0.000618	CcSEcCtD
Plerixafor—Dermatitis—Thiotepa—breast cancer	8.55e-05	0.000617	CcSEcCtD
Plerixafor—Dyspnoea—Paclitaxel—breast cancer	8.52e-05	0.000615	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRLR—breast cancer	8.52e-05	0.000862	CbGpPWpGaD
Plerixafor—Headache—Thiotepa—breast cancer	8.5e-05	0.000614	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL12—breast cancer	8.5e-05	0.00086	CbGpPWpGaD
Plerixafor—CXCR4—Disease—JAG2—breast cancer	8.5e-05	0.000859	CbGpPWpGaD
Plerixafor—Arthralgia—Docetaxel—breast cancer	8.45e-05	0.00061	CcSEcCtD
Plerixafor—Loss of consciousness—Capecitabine—breast cancer	8.45e-05	0.00061	CcSEcCtD
Plerixafor—Nausea—Vinorelbine—breast cancer	8.44e-05	0.00061	CcSEcCtD
Plerixafor—Dyspepsia—Paclitaxel—breast cancer	8.42e-05	0.000608	CcSEcCtD
Plerixafor—Asthenia—Irinotecan—breast cancer	8.41e-05	0.000607	CcSEcCtD
Plerixafor—Asthenia—Mitoxantrone—breast cancer	8.41e-05	0.000607	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	8.4e-05	0.000606	CcSEcCtD
Plerixafor—CXCR4—Disease—WNT1—breast cancer	8.38e-05	0.000847	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SLC2A2—breast cancer	8.32e-05	0.000841	CbGpPWpGaD
Plerixafor—Hypersensitivity—Fluorouracil—breast cancer	8.27e-05	0.000597	CcSEcCtD
Plerixafor—Dry mouth—Docetaxel—breast cancer	8.27e-05	0.000597	CcSEcCtD
Plerixafor—Haemoglobin—Methotrexate—breast cancer	8.26e-05	0.000597	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Paclitaxel—breast cancer	8.25e-05	0.000596	CcSEcCtD
Plerixafor—Fatigue—Paclitaxel—breast cancer	8.24e-05	0.000595	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GLI2—breast cancer	8.23e-05	0.000832	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VCP—breast cancer	8.23e-05	0.000832	CbGpPWpGaD
Plerixafor—Haemorrhage—Methotrexate—breast cancer	8.22e-05	0.000594	CcSEcCtD
Plerixafor—Asthenia—Gemcitabine—breast cancer	8.19e-05	0.000592	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	8.19e-05	0.000828	CbGpPWpGaD
Plerixafor—Arthralgia—Capecitabine—breast cancer	8.19e-05	0.000591	CcSEcCtD
Plerixafor—Pain—Paclitaxel—breast cancer	8.18e-05	0.00059	CcSEcCtD
Plerixafor—Constipation—Paclitaxel—breast cancer	8.18e-05	0.00059	CcSEcCtD
Plerixafor—CXCR4—Disease—MTR—breast cancer	8.15e-05	0.000824	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	8.13e-05	0.000587	CcSEcCtD
Plerixafor—Anaphylactic shock—Docetaxel—breast cancer	8.1e-05	0.000585	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—LEPR—breast cancer	8.1e-05	0.000819	CbGpPWpGaD
Plerixafor—Discomfort—Capecitabine—breast cancer	8.09e-05	0.000584	CcSEcCtD
Plerixafor—Pruritus—Gemcitabine—breast cancer	8.08e-05	0.000583	CcSEcCtD
Plerixafor—Nausea—Thiotepa—breast cancer	8.06e-05	0.000582	CcSEcCtD
Plerixafor—Diarrhoea—Irinotecan—breast cancer	8.02e-05	0.000579	CcSEcCtD
Plerixafor—Diarrhoea—Mitoxantrone—breast cancer	8.02e-05	0.000579	CcSEcCtD
Plerixafor—Dry mouth—Capecitabine—breast cancer	8.01e-05	0.000578	CcSEcCtD
Plerixafor—Shock—Docetaxel—breast cancer	7.97e-05	0.000576	CcSEcCtD
Plerixafor—Nervous system disorder—Docetaxel—breast cancer	7.95e-05	0.000574	CcSEcCtD
Plerixafor—Pruritus—Fluorouracil—breast cancer	7.94e-05	0.000573	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CALCA—breast cancer	7.9e-05	0.000799	CbGpPWpGaD
Plerixafor—Feeling abnormal—Paclitaxel—breast cancer	7.88e-05	0.000569	CcSEcCtD
Plerixafor—Skin disorder—Docetaxel—breast cancer	7.87e-05	0.000568	CcSEcCtD
Plerixafor—Gastrointestinal pain—Paclitaxel—breast cancer	7.82e-05	0.000564	CcSEcCtD
Plerixafor—Diarrhoea—Gemcitabine—breast cancer	7.81e-05	0.000564	CcSEcCtD
Plerixafor—Dizziness—Irinotecan—breast cancer	7.75e-05	0.00056	CcSEcCtD
Plerixafor—Haemoglobin—Epirubicin—breast cancer	7.73e-05	0.000558	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCL12—breast cancer	7.72e-05	0.000781	CbGpPWpGaD
Plerixafor—Shock—Capecitabine—breast cancer	7.72e-05	0.000557	CcSEcCtD
Plerixafor—Nervous system disorder—Capecitabine—breast cancer	7.69e-05	0.000555	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—breast cancer	7.69e-05	0.000555	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—AGTR1—breast cancer	7.69e-05	0.000777	CbGpPWpGaD
Plerixafor—Diarrhoea—Fluorouracil—breast cancer	7.68e-05	0.000555	CcSEcCtD
Plerixafor—Skin disorder—Capecitabine—breast cancer	7.62e-05	0.00055	CcSEcCtD
Plerixafor—Urticaria—Paclitaxel—breast cancer	7.6e-05	0.000548	CcSEcCtD
Plerixafor—Hyperhidrosis—Capecitabine—breast cancer	7.59e-05	0.000548	CcSEcCtD
Plerixafor—CXCR4—Disease—HSPA1B—breast cancer	7.57e-05	0.000766	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Epirubicin—breast cancer	7.56e-05	0.000546	CcSEcCtD
Plerixafor—Abdominal pain—Paclitaxel—breast cancer	7.56e-05	0.000546	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ARHGDIA—breast cancer	7.53e-05	0.000761	CbGpPWpGaD
Plerixafor—Vomiting—Mitoxantrone—breast cancer	7.45e-05	0.000538	CcSEcCtD
Plerixafor—Vomiting—Irinotecan—breast cancer	7.45e-05	0.000538	CcSEcCtD
Plerixafor—Immune system disorder—Methotrexate—breast cancer	7.43e-05	0.000536	CcSEcCtD
Plerixafor—Dizziness—Fluorouracil—breast cancer	7.43e-05	0.000536	CcSEcCtD
Plerixafor—Rash—Mitoxantrone—breast cancer	7.39e-05	0.000534	CcSEcCtD
Plerixafor—Rash—Irinotecan—breast cancer	7.39e-05	0.000534	CcSEcCtD
Plerixafor—Dermatitis—Irinotecan—breast cancer	7.39e-05	0.000533	CcSEcCtD
Plerixafor—Dermatitis—Mitoxantrone—breast cancer	7.39e-05	0.000533	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Docetaxel—breast cancer	7.38e-05	0.000533	CcSEcCtD
Plerixafor—Headache—Mitoxantrone—breast cancer	7.34e-05	0.00053	CcSEcCtD
Plerixafor—Headache—Irinotecan—breast cancer	7.34e-05	0.00053	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FST—breast cancer	7.34e-05	0.000742	CbGpPWpGaD
Plerixafor—Insomnia—Docetaxel—breast cancer	7.33e-05	0.000529	CcSEcCtD
Plerixafor—Paraesthesia—Docetaxel—breast cancer	7.28e-05	0.000525	CcSEcCtD
Plerixafor—CXCR4—Disease—ENO1—breast cancer	7.26e-05	0.000734	CbGpPWpGaD
Plerixafor—Vomiting—Gemcitabine—breast cancer	7.26e-05	0.000524	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HEY2—breast cancer	7.25e-05	0.000733	CbGpPWpGaD
Plerixafor—Dyspnoea—Docetaxel—breast cancer	7.23e-05	0.000522	CcSEcCtD
Plerixafor—Mental disorder—Methotrexate—breast cancer	7.2e-05	0.00052	CcSEcCtD
Plerixafor—Rash—Gemcitabine—breast cancer	7.2e-05	0.00052	CcSEcCtD
Plerixafor—Dermatitis—Gemcitabine—breast cancer	7.19e-05	0.000519	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RPS6KB2—breast cancer	7.16e-05	0.000724	CbGpPWpGaD
Plerixafor—Erythema—Methotrexate—breast cancer	7.16e-05	0.000517	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—breast cancer	7.16e-05	0.000517	CcSEcCtD
Plerixafor—Headache—Gemcitabine—breast cancer	7.15e-05	0.000516	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Capecitabine—breast cancer	7.15e-05	0.000516	CcSEcCtD
Plerixafor—Vomiting—Fluorouracil—breast cancer	7.14e-05	0.000515	CcSEcCtD
Plerixafor—Dyspepsia—Docetaxel—breast cancer	7.13e-05	0.000515	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—breast cancer	7.12e-05	0.000514	CcSEcCtD
Plerixafor—Insomnia—Capecitabine—breast cancer	7.1e-05	0.000512	CcSEcCtD
Plerixafor—Rash—Fluorouracil—breast cancer	7.08e-05	0.000511	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RGS2—breast cancer	7.08e-05	0.000716	CbGpPWpGaD
Plerixafor—Dermatitis—Fluorouracil—breast cancer	7.07e-05	0.000511	CcSEcCtD
Plerixafor—Paraesthesia—Capecitabine—breast cancer	7.05e-05	0.000509	CcSEcCtD
Plerixafor—Hypersensitivity—Paclitaxel—breast cancer	7.04e-05	0.000509	CcSEcCtD
Plerixafor—Headache—Fluorouracil—breast cancer	7.03e-05	0.000508	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CCL20—breast cancer	7e-05	0.000708	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Docetaxel—breast cancer	7e-05	0.000505	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—breast cancer	7e-05	0.000505	CcSEcCtD
Plerixafor—Dyspnoea—Capecitabine—breast cancer	7e-05	0.000505	CcSEcCtD
Plerixafor—Fatigue—Docetaxel—breast cancer	6.99e-05	0.000504	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—AGTR1—breast cancer	6.98e-05	0.000706	CbGpPWpGaD
Plerixafor—Nausea—Irinotecan—breast cancer	6.96e-05	0.000503	CcSEcCtD
Plerixafor—Nausea—Mitoxantrone—breast cancer	6.96e-05	0.000503	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—breast cancer	6.95e-05	0.000502	CcSEcCtD
Plerixafor—Pain—Docetaxel—breast cancer	6.93e-05	0.0005	CcSEcCtD
Plerixafor—Constipation—Docetaxel—breast cancer	6.93e-05	0.0005	CcSEcCtD
Plerixafor—Dyspepsia—Capecitabine—breast cancer	6.91e-05	0.000499	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—ITPR1—breast cancer	6.9e-05	0.000698	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGF3—breast cancer	6.87e-05	0.000694	CbGpPWpGaD
Plerixafor—Asthenia—Paclitaxel—breast cancer	6.86e-05	0.000495	CcSEcCtD
Plerixafor—Nausea—Gemcitabine—breast cancer	6.78e-05	0.00049	CcSEcCtD
Plerixafor—CXCR4—Disease—JAG1—breast cancer	6.78e-05	0.000685	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FASN—breast cancer	6.78e-05	0.000685	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TLE3—breast cancer	6.78e-05	0.000685	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LPAR1—breast cancer	6.78e-05	0.000685	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Capecitabine—breast cancer	6.77e-05	0.000489	CcSEcCtD
Plerixafor—Fatigue—Capecitabine—breast cancer	6.76e-05	0.000488	CcSEcCtD
Plerixafor—Pruritus—Paclitaxel—breast cancer	6.76e-05	0.000488	CcSEcCtD
Plerixafor—CXCR4—Disease—PARP1—breast cancer	6.75e-05	0.000683	CbGpPWpGaD
Plerixafor—Mental disorder—Epirubicin—breast cancer	6.74e-05	0.000487	CcSEcCtD
Plerixafor—Pain—Capecitabine—breast cancer	6.71e-05	0.000484	CcSEcCtD
Plerixafor—Constipation—Capecitabine—breast cancer	6.71e-05	0.000484	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HEY1—breast cancer	6.71e-05	0.000678	CbGpPWpGaD
Plerixafor—Erythema—Epirubicin—breast cancer	6.7e-05	0.000484	CcSEcCtD
Plerixafor—Feeling abnormal—Docetaxel—breast cancer	6.68e-05	0.000482	CcSEcCtD
Plerixafor—Nausea—Fluorouracil—breast cancer	6.67e-05	0.000481	CcSEcCtD
Plerixafor—CXCR4—Disease—CALCA—breast cancer	6.67e-05	0.000674	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Methotrexate—breast cancer	6.64e-05	0.000479	CcSEcCtD
Plerixafor—Gastrointestinal pain—Docetaxel—breast cancer	6.63e-05	0.000478	CcSEcCtD
Plerixafor—Flatulence—Epirubicin—breast cancer	6.6e-05	0.000476	CcSEcCtD
Plerixafor—CXCR4—Disease—RPS6—breast cancer	6.59e-05	0.000666	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—DLL1—breast cancer	6.58e-05	0.000665	CbGpPWpGaD
Plerixafor—Diarrhoea—Paclitaxel—breast cancer	6.54e-05	0.000472	CcSEcCtD
Plerixafor—CXCR4—Disease—FGF4—breast cancer	6.54e-05	0.000661	CbGpPWpGaD
Plerixafor—Feeling abnormal—Capecitabine—breast cancer	6.47e-05	0.000467	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HIST1H2BC—breast cancer	6.46e-05	0.000653	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HIST1H2BK—breast cancer	6.46e-05	0.000653	CbGpPWpGaD
Plerixafor—Malaise—Methotrexate—breast cancer	6.45e-05	0.000466	CcSEcCtD
Plerixafor—CXCR4—Disease—SLC2A1—breast cancer	6.44e-05	0.000651	CbGpPWpGaD
Plerixafor—Immune system disorder—Doxorubicin—breast cancer	6.43e-05	0.000464	CcSEcCtD
Plerixafor—Gastrointestinal pain—Capecitabine—breast cancer	6.42e-05	0.000463	CcSEcCtD
Plerixafor—Abdominal pain—Docetaxel—breast cancer	6.41e-05	0.000462	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GRB7—breast cancer	6.4e-05	0.000647	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDE4D—breast cancer	6.4e-05	0.000647	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CSF2—breast cancer	6.37e-05	0.000644	CbGpPWpGaD
Plerixafor—Dizziness—Paclitaxel—breast cancer	6.32e-05	0.000456	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TAB2—breast cancer	6.29e-05	0.000636	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TCF7L2—breast cancer	6.28e-05	0.000635	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—ITPR1—breast cancer	6.27e-05	0.000634	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CNR2—breast cancer	6.24e-05	0.000631	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—breast cancer	6.24e-05	0.00045	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—breast cancer	6.23e-05	0.00063	CbGpPWpGaD
Plerixafor—Urticaria—Capecitabine—breast cancer	6.23e-05	0.00045	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—MMP3—breast cancer	6.22e-05	0.000629	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Epirubicin—breast cancer	6.21e-05	0.000449	CcSEcCtD
Plerixafor—Abdominal pain—Capecitabine—breast cancer	6.2e-05	0.000448	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—breast cancer	6.2e-05	0.000447	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—breast cancer	6.11e-05	0.000441	CcSEcCtD
Plerixafor—Arthralgia—Methotrexate—breast cancer	6.09e-05	0.00044	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—DKK1—breast cancer	6.09e-05	0.000616	CbGpPWpGaD
Plerixafor—Vomiting—Paclitaxel—breast cancer	6.08e-05	0.000439	CcSEcCtD
Plerixafor—CXCR4—Disease—HSP90AA1—breast cancer	6.06e-05	0.000612	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.05e-05	0.000437	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—VEGFC—breast cancer	6.04e-05	0.000611	CbGpPWpGaD
Plerixafor—Malaise—Epirubicin—breast cancer	6.04e-05	0.000436	CcSEcCtD
Plerixafor—Rash—Paclitaxel—breast cancer	6.03e-05	0.000435	CcSEcCtD
Plerixafor—Dermatitis—Paclitaxel—breast cancer	6.02e-05	0.000435	CcSEcCtD
Plerixafor—Discomfort—Methotrexate—breast cancer	6.02e-05	0.000435	CcSEcCtD
Plerixafor—Syncope—Epirubicin—breast cancer	6.01e-05	0.000434	CcSEcCtD
Plerixafor—Headache—Paclitaxel—breast cancer	5.99e-05	0.000432	CcSEcCtD
Plerixafor—Hypersensitivity—Docetaxel—breast cancer	5.97e-05	0.000431	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JAG2—breast cancer	5.95e-05	0.000602	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PRL—breast cancer	5.89e-05	0.000596	CbGpPWpGaD
Plerixafor—Loss of consciousness—Epirubicin—breast cancer	5.89e-05	0.000425	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—WNT1—breast cancer	5.86e-05	0.000593	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PLA2G4A—breast cancer	5.85e-05	0.000592	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Methotrexate—breast cancer	5.84e-05	0.000422	CcSEcCtD
Plerixafor—Asthenia—Docetaxel—breast cancer	5.81e-05	0.00042	CcSEcCtD
Plerixafor—CXCR4—Disease—ADAM10—breast cancer	5.81e-05	0.000587	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CSF2—breast cancer	5.79e-05	0.000585	CbGpPWpGaD
Plerixafor—Hypersensitivity—Capecitabine—breast cancer	5.78e-05	0.000417	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—breast cancer	5.75e-05	0.000415	CcSEcCtD
Plerixafor—Pruritus—Docetaxel—breast cancer	5.73e-05	0.000414	CcSEcCtD
Plerixafor—Nervous system disorder—Methotrexate—breast cancer	5.73e-05	0.000414	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—breast cancer	5.7e-05	0.000412	CcSEcCtD
Plerixafor—Nausea—Paclitaxel—breast cancer	5.68e-05	0.00041	CcSEcCtD
Plerixafor—Skin disorder—Methotrexate—breast cancer	5.67e-05	0.00041	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.66e-05	0.000409	CcSEcCtD
Plerixafor—CXCR4—Disease—FGF10—breast cancer	5.65e-05	0.000571	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Methotrexate—breast cancer	5.65e-05	0.000408	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—breast cancer	5.63e-05	0.000407	CcSEcCtD
Plerixafor—Asthenia—Capecitabine—breast cancer	5.63e-05	0.000406	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—breast cancer	5.59e-05	0.000403	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—breast cancer	5.58e-05	0.000403	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—NOTCH4—breast cancer	5.56e-05	0.000562	CbGpPWpGaD
Plerixafor—Syncope—Doxorubicin—breast cancer	5.56e-05	0.000401	CcSEcCtD
Plerixafor—Pruritus—Capecitabine—breast cancer	5.55e-05	0.000401	CcSEcCtD
Plerixafor—Diarrhoea—Docetaxel—breast cancer	5.55e-05	0.0004	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GZMB—breast cancer	5.53e-05	0.000559	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Epirubicin—breast cancer	5.47e-05	0.000395	CcSEcCtD
Plerixafor—CXCR4—Disease—PDGFA—breast cancer	5.45e-05	0.000551	CbGpPWpGaD
Plerixafor—Loss of consciousness—Doxorubicin—breast cancer	5.45e-05	0.000393	CcSEcCtD
Plerixafor—Shock—Epirubicin—breast cancer	5.38e-05	0.000388	CcSEcCtD
Plerixafor—CXCR4—Disease—TGFBR2—breast cancer	5.37e-05	0.000543	CbGpPWpGaD
Plerixafor—Diarrhoea—Capecitabine—breast cancer	5.37e-05	0.000388	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AGTR2—breast cancer	5.36e-05	0.000542	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL2—breast cancer	5.36e-05	0.000542	CbGpPWpGaD
Plerixafor—Nervous system disorder—Epirubicin—breast cancer	5.36e-05	0.000387	CcSEcCtD
Plerixafor—Dizziness—Docetaxel—breast cancer	5.36e-05	0.000387	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Methotrexate—breast cancer	5.32e-05	0.000384	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—breast cancer	5.31e-05	0.000383	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—BMP2—breast cancer	5.3e-05	0.000536	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTHLH—breast cancer	5.3e-05	0.000536	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ITPR1—breast cancer	5.29e-05	0.000534	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Epirubicin—breast cancer	5.28e-05	0.000381	CcSEcCtD
Plerixafor—Insomnia—Methotrexate—breast cancer	5.28e-05	0.000381	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—breast cancer	5.28e-05	0.000381	CcSEcCtD
Plerixafor—CXCR4—Disease—STAT5A—breast cancer	5.25e-05	0.000531	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB4—breast cancer	5.25e-05	0.000531	CbGpPWpGaD
Plerixafor—Paraesthesia—Methotrexate—breast cancer	5.25e-05	0.000379	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.24e-05	0.000378	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—breast cancer	5.21e-05	0.000376	CcSEcCtD
Plerixafor—Dyspnoea—Methotrexate—breast cancer	5.21e-05	0.000376	CcSEcCtD
Plerixafor—Dizziness—Capecitabine—breast cancer	5.19e-05	0.000375	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—breast cancer	5.16e-05	0.000373	CcSEcCtD
Plerixafor—Vomiting—Docetaxel—breast cancer	5.15e-05	0.000372	CcSEcCtD
Plerixafor—Dyspepsia—Methotrexate—breast cancer	5.14e-05	0.000371	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—EDNRB—breast cancer	5.14e-05	0.000519	CbGpPWpGaD
Plerixafor—Rash—Docetaxel—breast cancer	5.11e-05	0.000369	CcSEcCtD
Plerixafor—Dermatitis—Docetaxel—breast cancer	5.11e-05	0.000369	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PGR—breast cancer	5.09e-05	0.000514	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SMAD4—breast cancer	5.08e-05	0.000514	CbGpPWpGaD
Plerixafor—Headache—Docetaxel—breast cancer	5.08e-05	0.000367	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—THBS1—breast cancer	5.06e-05	0.000512	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Doxorubicin—breast cancer	5.06e-05	0.000365	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Methotrexate—breast cancer	5.04e-05	0.000364	CcSEcCtD
Plerixafor—Fatigue—Methotrexate—breast cancer	5.04e-05	0.000364	CcSEcCtD
Plerixafor—Pain—Methotrexate—breast cancer	5e-05	0.000361	CcSEcCtD
Plerixafor—Vomiting—Capecitabine—breast cancer	4.99e-05	0.00036	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—breast cancer	4.98e-05	0.00036	CcSEcCtD
Plerixafor—Shock—Doxorubicin—breast cancer	4.98e-05	0.000359	CcSEcCtD
Plerixafor—CXCR4—Disease—HES1—breast cancer	4.96e-05	0.000502	CbGpPWpGaD
Plerixafor—Nervous system disorder—Doxorubicin—breast cancer	4.96e-05	0.000358	CcSEcCtD
Plerixafor—Rash—Capecitabine—breast cancer	4.95e-05	0.000357	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—breast cancer	4.94e-05	0.000357	CcSEcCtD
Plerixafor—Dermatitis—Capecitabine—breast cancer	4.94e-05	0.000357	CcSEcCtD
Plerixafor—CXCR4—Disease—NCOR1—breast cancer	4.94e-05	0.000499	CbGpPWpGaD
Plerixafor—Headache—Capecitabine—breast cancer	4.92e-05	0.000355	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—breast cancer	4.91e-05	0.000355	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—breast cancer	4.91e-05	0.000354	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—breast cancer	4.89e-05	0.000353	CcSEcCtD
Plerixafor—CXCR4—Disease—FGF1—breast cancer	4.88e-05	0.000494	CbGpPWpGaD
Plerixafor—Dyspnoea—Epirubicin—breast cancer	4.87e-05	0.000352	CcSEcCtD
Plerixafor—CXCR4—Disease—NRG1—breast cancer	4.85e-05	0.00049	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FLT1—breast cancer	4.83e-05	0.000488	CbGpPWpGaD
Plerixafor—Nausea—Docetaxel—breast cancer	4.81e-05	0.000348	CcSEcCtD
Plerixafor—Feeling abnormal—Methotrexate—breast cancer	4.81e-05	0.000347	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—breast cancer	4.81e-05	0.000347	CcSEcCtD
Plerixafor—CXCR4—Disease—H2AFX—breast cancer	4.81e-05	0.000486	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF3—breast cancer	4.81e-05	0.000486	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SQSTM1—breast cancer	4.81e-05	0.000486	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—breast cancer	4.78e-05	0.000484	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Methotrexate—breast cancer	4.78e-05	0.000345	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JAG1—breast cancer	4.75e-05	0.00048	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH3—breast cancer	4.73e-05	0.000478	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PARP1—breast cancer	4.73e-05	0.000478	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Epirubicin—breast cancer	4.72e-05	0.000341	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—breast cancer	4.71e-05	0.00034	CcSEcCtD
Plerixafor—Constipation—Epirubicin—breast cancer	4.67e-05	0.000337	CcSEcCtD
Plerixafor—Pain—Epirubicin—breast cancer	4.67e-05	0.000337	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CALCA—breast cancer	4.67e-05	0.000472	CbGpPWpGaD
Plerixafor—Nausea—Capecitabine—breast cancer	4.66e-05	0.000336	CcSEcCtD
Plerixafor—CXCR4—Disease—ERCC2—breast cancer	4.64e-05	0.000469	CbGpPWpGaD
Plerixafor—Urticaria—Methotrexate—breast cancer	4.64e-05	0.000335	CcSEcCtD
Plerixafor—Abdominal pain—Methotrexate—breast cancer	4.62e-05	0.000333	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RPS6—breast cancer	4.61e-05	0.000467	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.61e-05	0.000333	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FGF4—breast cancer	4.58e-05	0.000463	CbGpPWpGaD
Plerixafor—Insomnia—Doxorubicin—breast cancer	4.57e-05	0.00033	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CXCL12—breast cancer	4.56e-05	0.000461	CbGpPWpGaD
Plerixafor—Paraesthesia—Doxorubicin—breast cancer	4.54e-05	0.000328	CcSEcCtD
Plerixafor—CXCR4—Disease—ERBB3—breast cancer	4.54e-05	0.000459	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGFR2—breast cancer	4.53e-05	0.000458	CbGpPWpGaD
Plerixafor—Dyspnoea—Doxorubicin—breast cancer	4.51e-05	0.000326	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—breast cancer	4.5e-05	0.000325	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PAK1—breast cancer	4.48e-05	0.000453	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Epirubicin—breast cancer	4.47e-05	0.000323	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—breast cancer	4.45e-05	0.000321	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TCF7L2—breast cancer	4.4e-05	0.000445	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT2—breast cancer	4.38e-05	0.000443	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Doxorubicin—breast cancer	4.37e-05	0.000315	CcSEcCtD
Plerixafor—CXCR4—Disease—MTHFR—breast cancer	4.36e-05	0.000441	CbGpPWpGaD
Plerixafor—Fatigue—Doxorubicin—breast cancer	4.36e-05	0.000315	CcSEcCtD
Plerixafor—CXCR4—Disease—TERT—breast cancer	4.35e-05	0.00044	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—breast cancer	4.34e-05	0.000439	CbGpPWpGaD
Plerixafor—Urticaria—Epirubicin—breast cancer	4.34e-05	0.000313	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—breast cancer	4.33e-05	0.000312	CcSEcCtD
Plerixafor—Pain—Doxorubicin—breast cancer	4.33e-05	0.000312	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—breast cancer	4.32e-05	0.000312	CcSEcCtD
Plerixafor—Hypersensitivity—Methotrexate—breast cancer	4.3e-05	0.000311	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HSP90AA1—breast cancer	4.24e-05	0.000429	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH2—breast cancer	4.24e-05	0.000429	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGFR1—breast cancer	4.22e-05	0.000427	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—breast cancer	4.21e-05	0.000425	CbGpPWpGaD
Plerixafor—Asthenia—Methotrexate—breast cancer	4.19e-05	0.000303	CcSEcCtD
Plerixafor—Feeling abnormal—Doxorubicin—breast cancer	4.17e-05	0.000301	CcSEcCtD
Plerixafor—CXCR4—Disease—HIF1A—breast cancer	4.16e-05	0.000421	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Doxorubicin—breast cancer	4.14e-05	0.000299	CcSEcCtD
Plerixafor—Pruritus—Methotrexate—breast cancer	4.13e-05	0.000298	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRL—breast cancer	4.12e-05	0.000417	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AGTR1—breast cancer	4.12e-05	0.000417	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STK11—breast cancer	4.07e-05	0.000411	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ADAM10—breast cancer	4.07e-05	0.000411	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—breast cancer	4.03e-05	0.000291	CcSEcCtD
Plerixafor—CXCR4—Disease—CAV1—breast cancer	4.02e-05	0.000407	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PLG—breast cancer	4.02e-05	0.000406	CbGpPWpGaD
Plerixafor—Urticaria—Doxorubicin—breast cancer	4.02e-05	0.00029	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—breast cancer	4e-05	0.000289	CcSEcCtD
Plerixafor—Diarrhoea—Methotrexate—breast cancer	4e-05	0.000289	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—AKT2—breast cancer	3.98e-05	0.000402	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF10—breast cancer	3.95e-05	0.0004	CbGpPWpGaD
Plerixafor—Asthenia—Epirubicin—breast cancer	3.92e-05	0.000283	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—breast cancer	3.87e-05	0.000279	CcSEcCtD
Plerixafor—Dizziness—Methotrexate—breast cancer	3.86e-05	0.000279	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—breast cancer	3.82e-05	0.000386	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDGFA—breast cancer	3.82e-05	0.000386	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOS2—breast cancer	3.78e-05	0.000383	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFBR2—breast cancer	3.76e-05	0.00038	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOTCH1—breast cancer	3.75e-05	0.000379	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—breast cancer	3.74e-05	0.00027	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—breast cancer	3.73e-05	0.000269	CcSEcCtD
Plerixafor—Vomiting—Methotrexate—breast cancer	3.71e-05	0.000268	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ITPR1—breast cancer	3.7e-05	0.000374	CbGpPWpGaD
Plerixafor—Rash—Methotrexate—breast cancer	3.68e-05	0.000266	CcSEcCtD
Plerixafor—Dermatitis—Methotrexate—breast cancer	3.68e-05	0.000266	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ERBB4—breast cancer	3.68e-05	0.000372	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP3—breast cancer	3.68e-05	0.000372	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT5A—breast cancer	3.68e-05	0.000372	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—breast cancer	3.67e-05	0.000371	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KIT—breast cancer	3.67e-05	0.000371	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APC—breast cancer	3.67e-05	0.000371	CbGpPWpGaD
Plerixafor—Headache—Methotrexate—breast cancer	3.66e-05	0.000264	CcSEcCtD
Plerixafor—Asthenia—Doxorubicin—breast cancer	3.63e-05	0.000262	CcSEcCtD
Plerixafor—CXCR4—Disease—EGF—breast cancer	3.62e-05	0.000366	CbGpPWpGaD
Plerixafor—Dizziness—Epirubicin—breast cancer	3.61e-05	0.000261	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—breast cancer	3.58e-05	0.000258	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SMAD4—breast cancer	3.56e-05	0.00036	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1R—breast cancer	3.54e-05	0.000358	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—breast cancer	3.52e-05	0.000356	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HES1—breast cancer	3.48e-05	0.000352	CbGpPWpGaD
Plerixafor—Vomiting—Epirubicin—breast cancer	3.48e-05	0.000251	CcSEcCtD
Plerixafor—Nausea—Methotrexate—breast cancer	3.47e-05	0.00025	CcSEcCtD
Plerixafor—Diarrhoea—Doxorubicin—breast cancer	3.46e-05	0.00025	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—NCOR1—breast cancer	3.46e-05	0.00035	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PLA2G4A—breast cancer	3.46e-05	0.00035	CbGpPWpGaD
Plerixafor—Rash—Epirubicin—breast cancer	3.45e-05	0.000249	CcSEcCtD
Plerixafor—CXCR4—Disease—BRAF—breast cancer	3.45e-05	0.000348	CbGpPWpGaD
Plerixafor—Dermatitis—Epirubicin—breast cancer	3.44e-05	0.000249	CcSEcCtD
Plerixafor—Headache—Epirubicin—breast cancer	3.42e-05	0.000247	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CSF2—breast cancer	3.42e-05	0.000346	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF1—breast cancer	3.42e-05	0.000346	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—RAF1—breast cancer	3.41e-05	0.000345	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRG1—breast cancer	3.39e-05	0.000343	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—H2AFX—breast cancer	3.37e-05	0.000341	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—breast cancer	3.37e-05	0.00034	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT2—breast cancer	3.35e-05	0.000339	CbGpPWpGaD
Plerixafor—Dizziness—Doxorubicin—breast cancer	3.34e-05	0.000241	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—E2F1—breast cancer	3.34e-05	0.000338	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—breast cancer	3.33e-05	0.000337	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—breast cancer	3.25e-05	0.000234	CcSEcCtD
Plerixafor—CXCR4—Disease—PIK3CD—breast cancer	3.22e-05	0.000326	CbGpPWpGaD
Plerixafor—Vomiting—Doxorubicin—breast cancer	3.22e-05	0.000232	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SPP1—breast cancer	3.21e-05	0.000325	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—breast cancer	3.2e-05	0.000324	CbGpPWpGaD
Plerixafor—Rash—Doxorubicin—breast cancer	3.19e-05	0.00023	CcSEcCtD
Plerixafor—CXCR4—Disease—SERPINE1—breast cancer	3.19e-05	0.000322	CbGpPWpGaD
Plerixafor—Dermatitis—Doxorubicin—breast cancer	3.19e-05	0.00023	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ERBB3—breast cancer	3.18e-05	0.000321	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGFR2—breast cancer	3.17e-05	0.000321	CbGpPWpGaD
Plerixafor—Headache—Doxorubicin—breast cancer	3.17e-05	0.000229	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL2—breast cancer	3.06e-05	0.000309	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—breast cancer	3.05e-05	0.000308	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOS3—breast cancer	3.04e-05	0.000308	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—breast cancer	3e-05	0.000217	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FGFR1—breast cancer	2.96e-05	0.000299	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HIF1A—breast cancer	2.91e-05	0.000295	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MDM2—breast cancer	2.89e-05	0.000292	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RAF1—breast cancer	2.88e-05	0.000291	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—breast cancer	2.85e-05	0.000288	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LEP—breast cancer	2.84e-05	0.000288	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CAV1—breast cancer	2.82e-05	0.000285	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTOR—breast cancer	2.81e-05	0.000284	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CB—breast cancer	2.81e-05	0.000284	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD4—breast cancer	2.8e-05	0.000283	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KDR—breast cancer	2.79e-05	0.000282	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—breast cancer	2.78e-05	0.000281	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ESR1—breast cancer	2.72e-05	0.000275	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FN1—breast cancer	2.68e-05	0.000271	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NFKBIA—breast cancer	2.65e-05	0.000268	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—breast cancer	2.64e-05	0.000267	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH1—breast cancer	2.62e-05	0.000265	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—breast cancer	2.57e-05	0.00026	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APC—breast cancer	2.57e-05	0.00026	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KIT—breast cancer	2.57e-05	0.00026	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGF—breast cancer	2.54e-05	0.000257	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—breast cancer	2.49e-05	0.000252	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK3—breast cancer	2.46e-05	0.000249	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1A—breast cancer	2.43e-05	0.000246	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—breast cancer	2.43e-05	0.000245	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—breast cancer	2.41e-05	0.000244	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1—breast cancer	2.35e-05	0.000238	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT2—breast cancer	2.35e-05	0.000237	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—breast cancer	2.34e-05	0.000236	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—breast cancer	2.26e-05	0.000228	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SRC—breast cancer	2.25e-05	0.000228	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—breast cancer	2.23e-05	0.000226	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SERPINE1—breast cancer	2.23e-05	0.000226	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—breast cancer	2.21e-05	0.000223	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—breast cancer	2.17e-05	0.000219	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOS3—breast cancer	2.13e-05	0.000215	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK3—breast cancer	2.07e-05	0.00021	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—breast cancer	2.03e-05	0.000205	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MDM2—breast cancer	2.02e-05	0.000204	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—breast cancer	2.02e-05	0.000204	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RAF1—breast cancer	2.01e-05	0.000204	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFB1—breast cancer	2.01e-05	0.000203	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RELA—breast cancer	2.01e-05	0.000203	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—breast cancer	1.99e-05	0.000202	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—breast cancer	1.97e-05	0.000199	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MTOR—breast cancer	1.97e-05	0.000199	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—breast cancer	1.97e-05	0.000199	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—breast cancer	1.89e-05	0.000191	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—breast cancer	1.88e-05	0.00019	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—breast cancer	1.86e-05	0.000188	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—breast cancer	1.85e-05	0.000187	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—breast cancer	1.83e-05	0.000185	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—breast cancer	1.81e-05	0.000183	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—breast cancer	1.81e-05	0.000183	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—breast cancer	1.8e-05	0.000182	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—breast cancer	1.76e-05	0.000178	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JUN—breast cancer	1.76e-05	0.000178	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—breast cancer	1.74e-05	0.000176	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—breast cancer	1.71e-05	0.000173	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—breast cancer	1.71e-05	0.000173	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1A—breast cancer	1.7e-05	0.000172	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—breast cancer	1.7e-05	0.000172	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK8—breast cancer	1.66e-05	0.000168	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—breast cancer	1.66e-05	0.000168	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—breast cancer	1.58e-05	0.00016	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SRC—breast cancer	1.58e-05	0.000159	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—breast cancer	1.53e-05	0.000155	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—breast cancer	1.52e-05	0.000154	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—breast cancer	1.52e-05	0.000153	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK3—breast cancer	1.45e-05	0.000147	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—breast cancer	1.41e-05	0.000143	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFB1—breast cancer	1.41e-05	0.000142	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—breast cancer	1.4e-05	0.000141	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—breast cancer	1.38e-05	0.00014	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—breast cancer	1.3e-05	0.000132	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—breast cancer	1.2e-05	0.000121	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—breast cancer	1.16e-05	0.000117	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—breast cancer	1.11e-05	0.000112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—breast cancer	1.06e-05	0.000107	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—breast cancer	9.79e-06	9.9e-05	CbGpPWpGaD
